New hope for MSA patients: drug eases dangerous blood pressure drops

NCT ID NCT02071459

First seen Apr 11, 2026 · Last updated May 08, 2026 · Updated 3 times

Summary

This study tested a drug called droxidopa (L-threo DOPS) to see if it could reduce symptoms of orthostatic hypotension—dizziness and fainting when standing up—in people with multiple system atrophy (MSA). Over 100 adults with MSA took either the drug or a placebo for 12 weeks. The goal was to measure changes in symptom scores and blood pressure. The trial is complete, and results may help manage this challenging symptom.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SYSTEM ATROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHRU de lille

    Lille, 59037, France

  • CHU Pontchaillou

    Rennes, 35033, France

  • CHU bordeaux

    Bordeaux, France

  • CHU de Clermont-Ferrand

    Clermont-Ferrand, 63000, France

  • CHU de Dijon

    Dijon, 21000, France

  • CHU de Poitiers

    Poitiers, 86021, France

  • CHU de Rouen

    Rouen, 76031, France

  • CHU de limoges

    Limoges, 87042, France

  • Centre hospitalier d'Angers

    Angers, 49933, France

  • Hôpital G. & R. Laennec

    Nantes, 44093, France

  • Hôpital La Timone

    Marseille, 13000, France

  • Hôpital Pitié-Salpétrière

    Paris, 75013, France

  • chu de Strasbourg

    Strasbourg, 67091, France

Conditions

Explore the condition pages connected to this study.